Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program

Autor: Jules L.L.M. Coenen, Evert-Jan F. M. de Kruijf, Peter A. W. te Boekhorst, Joost T. M. de Wolf, Gerjo A. Velders, Fenna H. Heyning, Alex L. Imholz, Gert J. Ossenkoppele, Canan Alhan, M. C. Kappers-Klunne, Christine M. Segeren, Jan Koedam, Wies L. Vasmel, Ankie M. T. Van der Velden, Gerda Veth, Gerwin Huls, Arjan A. van de Loosdrecht, Imane Abouyahya, Theresia M. Westers, Erwin V. Planken, H.R. Koene, Petra Muus

Publikováno v: Leukemia & Lymphoma, 54, 4, pp. 874-7
Abouyahya, I, Alhan, C, Westers, T M, te Boekhorst, P A, Kappers-Klunne, MC, Coenen, J L, Heyning, F H, Huls, G A, de Wolf, JT, Imholz, A L, Koene, H R, Veth, G, de Kruijf, E J F M, Muus, P, Planken, E V, Segeren, C M, Vasmel, W L, van der Velden, A M, Velders, G A, Koedam, J, Ossenkoppele, G J & van de Loosdrecht, A A 2013, ' Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program ', Leukemia and Lymphoma, vol. 54, no. 4, pp. 874-877 . https://doi.org/10.3109/10428194.2012.728702
Leukemia and Lymphoma, 54(4), 874-877. Informa Healthcare
Leukemia & Lymphoma, 54, 874-7
Leukemia and Lymphoma, 54(4), 874-877. TAYLOR & FRANCIS LTD
Leukemia & Lymphoma, 54(4), 874-877

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of hematopoietic stem cell disorders characterized by dysplasia resulting in cytopenia in one or more cell lineages. The World Health ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a23ed24a02b861b0d8dad261ce450f08
https://pubmed.ncbi.nlm.nih.gov/22971215